If caught before metastasis, many malignant oral masses can be removed, leaving the patient with little to no facial deformity and a functional bite. Here’s an overview of the types of malignant oral masses you’re likely to encounter, as well as what to do about them.
Common oral malignancies
Here are the most commonly diagnosed malignant oral tumors in dogs and cats:
Malignant melanoma. Malignant melanoma is a locally aggressive tumor that’s common in dogs and rare in cats and often metastasizes to the lungs (Figures 1A and 1B). Aggressive surgical excision, including partial mandibulectomy or maxillectomy, is the treatment of choice. Tumor sizes less than 2 cm carry a better prognosis than those greater than 4 cm.
However, radiation may have a role in effectively treating the primary tumor. In cases deemed nonresectable, or if an owner is unwilling to pursue surgery, radiation therapy has a high response rate (70% to 90%). Most protocols utilized are classified as hypofractionated in that they require only a few treatments, but each treatment has a high dose, or fraction. This involves three to four weekly fractions of 8 Gray or six weekly fractions of 6 Gray.
Side effects, including oral mucositis, are generally mild and self-limiting with hypofractionated protocols. Similar to surgery, patients treated with radiation therapy may achieve local control but generally succumb to metastatic disease. Survival times of seven to nine months are common.
The Oncept Canine Melanoma Vaccine, DNA (Merial), is administered in stages II and III of canine oral melanoma and can decrease recurrence in some cases after removal or debulking of the primary tumor. The glycoprotein tyrosinase, which produces melanin found in melanoma cells, is the vaccine’s targeted antigen. The vaccine appears to be effective in cases of amelanotic melanoma too.
In a 2016 study that retrospectively reviewed the outcome and survival of 32 dogs affected by oral melanoma that were treated with a combination of surgery and the xenogeneic DNA vaccination (with the addition of radiotherapy in some cases), the overall median survival time was 335 days, and the overall median progression-free survival (PFS) was 160 days.1 Disease stage, surgical margin completeness and vaccine administration delay did not appear to statistically influence survival or PFS, though these results may reflect the study’s low statistical power due to small numbers.
Squamous cell carcinoma. Like malignant melanoma, squamous cell carcinoma is a locally aggressive tumor (Figure 2). Oral squamous cell carcinoma in dogs rarely metastasizes unless it affects the tongue or tonsil, and when it does, abdominal ultrasound is indicated as part of staging because distant metastasis is more common to the liver and spleen than to the lungs.
Surgical excision is the primary treatment of choice for macroscopic oral squamous cell carcinoma in dogs, followed by radiation therapy for microscopic disease. Local recurrence is common. Piroxicam, a nonsteroidal anti-inflammatory (NSAID) agent given orally at a dosage of 0.3 mg/kg every other day, can be used for palliation with a median survival time of 180 days in dogs in one monotherapy study.2 A slightly higher median survival time (272 days) was achieved when piroxicam was combined with cisplatin or carboplatin.3
A recent study of 87 dogs affected by nonmelanotic oral malignancies revealed that dogs undergoing postoperative radiotherapy after incomplete excision of oral squamous cell carcinomas had a significantly longer mean survival time (2,051 days) than dogs with incompletely excised tumors and no radiotherapy (181 days).4
Squamous cell carcinoma is the most common oral tumor in cats and carries a grave prognosis if located caudally or if it affects the base of the tongue. If located rostrally, surgery is the treatment of choice when clean, wide (at least 2-cm) margins can be obtained (Figure 3).
The NSAID meloxicam may have several beneficial effects in treating feline squamous cell carcinoma, including pain relief and reduced inflammation-associated neoplasia and edema. In the United States, meloxicam is licensed only as a one-time injection for perioperative pain in cats. In Australia and Europe, low doses (0.01-0.03 mg/kg a day) have been used to treat osteoarthritis in cats without significant side effects.
Fibrosarcoma. Diagnosed most commonly in the maxillae of large-breed dogs, fibrosarcoma is locally invasive but infrequently metastasizes to the lungs (Figure 4). It is the second most common oral malignancy in cats (after squamous cell carcinoma). A subset of fibrosarcomas has been recognized in which the tumors appear histologically low-grade yet behave as high-grade malignancies biologically (hi-lo).
As with squamous cell carcinoma, aggressive surgical excision that includes part of the dog's or cat’s mandible or maxilla is necessary. Radiation has been recommended to treat microscopic disease in fibrosarcoma tumors that are too large to obtain adequate margins. Hi-lo fibrosarcomas carry a poor prognosis regardless of surgery or radiation therapy. This may be partly due to the fact that most are associated with the maxilla and are thus more difficult to completely excise.
Osteosarcoma. Although malignant, oral osteosarcoma, which usually occurs in the mandible of dogs, may not be as aggressive as osteosarcoma of the appendicular skeleton in the dog (Figure 5). Osteosarcoma is rare in cats.
In a study of 51 dogs with osteosarcoma treated with partial mandibulectomy alone (32 dogs); partial mandibulectomy and chemotherapy (10 dogs); partial mandibulectomy and radiation therapy (3 dogs); partial mandibulectomy, radiation therapy, and chemotherapy (4 dogs); and radiation therapy alone (2 dogs), the group treated with surgery alone achieved a 1-year survival rate of 71%, compared with the entire group’s 1-year survival rate of 60%.5
In cases of maxillary osteosarcoma in both dogs and cats, recurrence is common after surgery. Chemotherapy and radiation in the treatment of oral osteosarcoma have not been associated with an increase in survival.
For a quick reference of all the oral tumors that can affect dogs and cats, see the sidebar, "Oral malignancy nomenclature," on page 1.
How to handle oral malignancies
Diagnosing your canine and feline patients is only the first step. Here’s what to consider next:
Talk frankly with the client. There can be little benefit from attempting to sugarcoat the diagnosis. If the mass is large, located caudally or has been present for a while, the prognosis is generally poor. Recently diagnosed small masses that are located rostrally generally carry a good prognosis when surgical excision with wide clean margins can be obtained. In some of these cases, radiation therapy combined with surgery adds to the favorable prognosis.
Find out more about the mass and the patient. Three-view thoracic radiographs need to be examined for metastasis. If present, surgery can still be performed, but the prognosis for long-term success is poor.
Further staging should include intraoral radiographs of the mass. The availability of computed tomography and cone beam computed tomography is a game-changer in treatment planning for oral masses in that they allow the practitioner to better view the whole iceberg instead of only the tip. The majority of malignant tumors will have evidence of bony involvement at the time of diagnosis; however, radiographic evidence of lysis does not occur until 50% of the bone has become demineralized (Figure 6).
Surgery. In cases where metastasis is not present, the chance to cut is a chance to save—especially if excision can be accomplished with at least 2 cm of clean surgical margins in all directions. (Note: It's the “in all directions” part that often creates a challenge.)
Maxillectomy and mandibulectomy nomenclature
Here’s an overview of your surgical options:
Partial mandibulectomy: The surgical removal (en bloc) of part of the mandible and surrounding soft tissues; also called a unilateral rostral mandibulectomy (Figures 7A-7C).
Mandibular rim excision: A form of partial mandibulectomy in which the ventral border of the mandible is maintained (Figures 8A-8C).
Segmental mandibulectomy: A form of partial mandibulectomy in which a full dorsoventral segment of the mandible is removed; also called a central mandibulectomy (Figures 9A and 9B).
Bilateral partial mandibulectomy: The surgical removal of parts of the left and right mandibles and surrounding soft tissues; also called a bilateral rostral mandibulectomy (Figures 10A-10C).
Total mandibulectomy: The surgical removal of one mandible and surrounding soft tissues; also called a unilateral mandibulectomy (Figure 11).
Partial maxillectomy: Surgical removal (en bloc) of part of the maxilla and/or other facial bones and surrounding soft tissues; also called a unilateral rostral maxillectomy (Figures 12A-12H).
Bilateral partial maxillectomy: Surgical removal of parts of the left and right maxillae and/or other facial bones and surrounding soft tissues; also called a bilateral rostral maxillectomy (Figures 13A and 13B).
The bottom line? If you can catch and treat malignant masses before metastasis, there’s hope for either a cure or at least a happier patient.
Stay tuned for the next installment, because “P” is for perioceuticals and periodontal sealants.
Treggiari E, Grant JP, North SM. A retrospective review of outcome and survival following surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma. J Vet Med Sci 2016;78(5):845-850.
Schmidt BR, Glickman NW, DeNicola DB, et al. Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 2001;218(11):1783-1786.
Boria PA, Murry DJ, Bennett PF, et al. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 2004;224(3):388-394.
Riggs J, Adams V, Hermer J, et al. Outcomes following surgical excision or surgical excision combined with adjunctive, hypofractionated radiotherapy in dogs with oral squamous cell carcinoma or fibrosarcoma. J Am Vet Med Assoc 2018;253(1):73-83.
Straw RC, Powers BE, Klausner J, et al. Canine mandibular osteosarcoma: 51 cases (1980-1992). J Am Anim Hosp Assoc 1996;32(3):257-262.